Abstract

This report concerns a drug, AL-0770 (2, 4-diamino-6-phenyl-s-triazine, Armour Pharmaceutical Company) which, when administered to intact human subjects, causes an acute rise in plasma corticosteroids without other evidence of stress. Our study was undertaken because screening tests by the company had detected an anti-inflammatory action dependent upon intact pituitary and adrenal glands and accompanied by evidence of adrenal cortical stimulation.

The study was carried out in a double-blind crossover fashion with balanced randomized allocation of active or placebo treatments in 8 normal human volunteers. The subjects were fasted after midnight except for water. At approximately 8:30 AM an intravenous cannula was inserted and a blood sample drawn, after which the cannula was heparinized and taped in place. Additional blood samples were taken at half-hour intervals over a period of 4 hours. All blood samples were immediately placed in ice and soon separated and the plasma frozen for later assay of fluorogenic corticosteroids (1) and immunoreactive TSH (thyrotrophin) (2). One hour after insertion of the cannula either the coded drug, 300 mg, or placebo tablets of identical appearance and taste were administered. On a second day the study was repeated with substitution of the alternate tablets.

This content is only available as a PDF.
You do not currently have access to this article.